Risk of cardiometabolic outcomes among women with a history of pelvic inflammatory disease: a retrospective matched cohort study from the UK

Table 2 Incidence rates and hazard ratios for composite cardiovascular disease (CVD) and CVD subtypes for women with a history of PID compared to those without a history of PID

	Composite CVD		Ischaemic heart disease		Cerebrovascular disease		Heart failure
	Exposed	Unexposed	Exposed	Unexposed	Exposed	Unexposed	Exposed	Unexposed
Population	19,559	72,994	19,659	73,305	19,687	73,400	19,747	73,605
Events, n (%)	184	531	86	228	100	283	33	120
Person-years	126,220.7	413,438.4	127,279.9	416,644.2	127,453.4	417,432.6	128,107.8	419,306.3
Crude incidence rate/1000 person years	1.5	1.3	0.7	0.5	0.8	0.7	0.3	0.3
Crude HR (95% CI)	1.11 (0.94–1.31)		1.20 (0.93–1.54)		1.13 (0.90–1.42)		0.87 (0.59–1.28)
P-value	0.238		0.154		0.289		0.486
Adjusted HR (95% CI)	1.10 (0.93–1.30)		1.19 (0.93–1.53)		1.13 (0.90–1.43)		0.92 (0.62–1.35)
P-value	0.275		0.176		0.284		0.671

Model adjusted for age, Townsend deprivation quintile, BMI, smoking status, lipid-lowering medication (current users, with a record of a prescription within 60 days prior to index date), diabetes mellitus hypertension contraceptive use (current users, defined as those prescribed combined oral contraceptive pills within the last 365 days prior to cohort entry) and reproductive conditions (premature delivery, miscarriage, stillbirths, gestational diabetes mellitus, polycystic ovary syndrome, pre-eclampsia, endometriosis
CVD, composite CVD, HR, Hazard ratio,

ISSN: 1472-6874